Recently, we reported that the administration of trastuzumab, in patients with HER2-negative early breast cancer who had detectable HER2-positive CTCs after the completion of adjuvant chemotherapy, resulted in a significant reduction of clinical relapses and a longer disease-free survival compared to patients who received only adjuvant chemotherapy [19]. This evidence concerns the gene ERBB2 and breast carcinoma.